Rosario Yerbes

Dr. Rosario Yerbes

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2006 in Cancer Research
Verified
Journal Article
Closed access
CPCarmen Palacios
Carmen Palacios
RYRosario Yerbes
Rosario Yerbes
ALAbelardo Lopez-Rivas
Abelardo Lopez-Rivas
The cyclin-dependent kinase inhibitor flavopiridol is undergoing clinical trials as an antitumor drug. We show here that pretreatment of different human breast cancer cell lines with flavopiridol facilitates tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)–induced apoptosis. In breast tumor cells, apoptosis induction by TRAIL is blocked at the level of apical caspase-8 activation. Flavopiridol treatment enhances TRAIL-induced formation of death-inducing signaling complex and early processing of procaspase-8. Subsequently, a TRAIL-induced, mitochondria-operated pathway of apoptosis is activated in cells treated with flavopiridol. Down-regulation of cellular FLICE-inhibitory proteins (c-FLIP; c-FLIPL and c-FLIPS) is observed on flavopiridol treatment. c-FLIP loss and apoptosis sensitization by flavopiridol are both prevented in cells treated with an inhibitor of the ubiquitin-proteasome system. Furthermore, targeting c-FLIP directly with small interfering RNA oligonucleotides also sensitizes various human breast tumor cell lines to TRAIL-induced apoptosis. Our results indicate that flavopiridol sensitizes breast cancer cells to TRAIL-induced apoptosis by facilitating early events in the apoptotic pathway, and this combination treatment could be regarded as a potential therapeutic tool against breast tumors. (Cancer Res 2006; 66(17): 8858-69)

13 March 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
RMRosa Martín-Pérez
Rosa Martín-Pérez
CPCarmen Palacios
Carmen Palacios
RYRosario Yerbes
Rosario Yerbes
ACAna Cano-González
Ana Cano-González
DIDaniel Iglesias-Serret
Daniel Iglesias-Serret
ALAbelardo Lopez-Rivas
Abelardo Lopez-Rivas
HER2/Neu/ERBB2 is a receptor tyrosine kinase overexpressed in approximately 20% of human breast tumors. Truncated or mutant isoforms that show increased oncogenicity compared with the wild-type receptor are found in many breast tumors. Here, we report that constitutively active ERBB2 sensitizes human breast epithelial cells to agents that induce endoplasmic reticulum stress, altering the unfolded protein response (UPR) of these cells. Deregulation of the ERK, AKT, and mTOR activities elicited by mutant ERBB2 was involved in mediating this differential UPR response, elevating the response to endoplasmic reticulum stress, and apoptotic cell death. Mechanistic investigations revealed that the increased sensitivity of mutant ERBB2-expressing cells to endoplasmic reticulum stress relied upon a UPR effector signaling involving the PERK–ATF4–CHOP pathway, upregulation of the proapoptotic cell surface receptor TRAIL-R2, and activation of proapoptotic caspase-8. Collectively, our results offer a rationale for the therapeutic exploration of treatments inducing endoplasmic reticulum stress against mutant ERBB2-expressing breast tumor cells. Cancer Res; 74(6); 1766–77. ©2014 AACR.

28 July 2016 in Oncotarget
Verified
Journal Article
Open access
RSRobin Schmitz
Robin Schmitz
AVAida Freire Valls
Aida Freire Valls
RYRosario Yerbes
Rosario Yerbes
SRSophie von Richter
Sophie von Richter
CKChristoph Kahlert
Christoph Kahlert
Thomas SchmidtThomas Schmidt
Thomas Schmidt
TAM receptors Tyro3 and Mer as novel targets in colorectal cancer

7 December 2011 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
RYRosario Yerbes
Rosario Yerbes
CPCarmen Palacios
Carmen Palacios
ALAbelardo Lopez-Rivas
Abelardo Lopez-Rivas

6 May 2008 in Cell Research
Verified
Journal Article
Closed access
GOGustavo Ortiz-Ferrón
Gustavo Ortiz-Ferrón
RYRosario Yerbes
Rosario Yerbes
AEAdriana Eramo
Adriana Eramo
ALAna I López-Pérez
Ana I López-Pérez
RMRuggero De Maria
Ruggero De Maria
ALAbelardo Lopez-Rivas
Abelardo Lopez-Rivas